Publications by authors named "D A Yardley"

Claim this Profile
R
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, John Crown

JAMA Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Sarah Sammons, Denise A Yardley, Priyanka Sharma, Vijayakrishna K Gadi, Mark Pegram

Oncol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.
Anna Weiss, Qingchun Jin, Nabihah Tayob, Eileen Wrabel, Michelle DeMeo, Denise Yardley

Ann Surg Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
J Crown, D Stroyakovskii, D A Yardley, C-S Huang, P A Fasching

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial.
Sherene Loi, Roberto Salgado, Giuseppe Curigliano, Roberto Iván Romero Díaz, Suzette Delaloge, Denise A Yardley

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis